TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

S Stintzing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.